Want to see DYN full AI Analyst Report?

Dyne Therapeutics (DYN) Price & Analysis

473 Followers

DYN Stock Chart & Stats

$20.41

-$0.74(-3.10%)

At close: Jan 08 4:00 PM EST

$20.41

-$0.74(-3.10%)

Day’s Range― - ―

52-Week Range$8.88 - $25.00

Previous CloseN/A

Volume117.44K

Average Volume (3M)2.12M

Market Cap

$3.92B

Enterprise Value$2.19K

Total Cash (Recent Filing)$972.16M

Total Debt (Recent Filing)$19.30M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Jul 30, 2026

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.22

Shares Outstanding165,313,800

10 Day Avg. Volume2,039,199

30 Day Avg. Volume2,122,427

Financial Highlights & Ratios

PEG Ratio-1.90

Price to Book (P/B)2.58

Price to Sales (P/S)0.00

P/FCF Ratio-6.20

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$40.33

Price Target Upside97.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-3.09

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FORCE PlatformDyne’s FORCE delivery platform is a durable scientific asset enabling targeted payload delivery to muscle. Platform-driven programs can create multiple asset opportunities, attract partners and licensing deals, and provide structural competitive advantage across neuromuscular indications beyond any single program.

BLA Priority Review For DYNE-251Priority Review and an explicit PDUFA date mark a structural regulatory milestone that could materially de-risk the lead DMD program. Approval would transition Dyne toward commercialization, enable recurring revenue streams, and validate clinical and regulatory execution across the broader pipeline.

Low Leverage And Substantial EquityVery low debt levels and sizable shareholders’ equity provide financing flexibility and reduce near-term solvency risk. This balance-sheet strength supports continued R&D and optionality for milestone financing, partnerships, or staged capital raises while advancing registrational programs.

Bears Say

No Revenue; Widening LossesDyne is pre‑commercial with no product revenue and materially widening net losses. Persistent negative operating leverage means the company cannot self-fund its growth today; absent program approvals or large partnerships, sustained losses increase dependence on external financing over the medium term.

Significant, Worsening Cash BurnOperating losses translate into sizable negative cash flow and accelerating free cash burn. Real cash outflows erode runway and force reliance on financing; this structural cash consumption raises dilution risk and constrains the company’s ability to self‑finance late‑stage activities absent commercialization or major partnerships.

Reliance On External Capital And Encumbered AssetsManagement has expanded debt facilities (with pledged IP/assets) and increased authorized shares, signaling structural reliance on external capital. These moves preserve flexibility but raise medium‑term dilution and collateralization risks that can constrain strategic options and affect long‑term shareholder value.

Dyne Therapeutics News

Citi sees intensifying competition for Sarepta from Dyne Therapeutics

Citi sees increased competition for Sarepta (SRPT) after the FDA accepted Dyne Therapeutics’ (DYN) application for z-rostudirsen in...

3h ago

DYN

SRPT

Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA

Dyne Therapeutics (DYN) announced that the FDA has accepted for review the biologics license application, or BLA, for...

1d ago

DYN

Dyne Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Dyne Therapeutics (DYN) with a Buy rating and no price target The company’s...

25d ago

DYN

Dyne Therapeutics Advances DYNE-251 With FDA Priority Review

Dyne Therapeutics ( ($DYN) ) just unveiled an announcement. On July 20, 2026, Dyne Therapeutics, Inc. announced that...

1d ago

DYN

Joseph Thome Initiates Buy on Dyne Therapeutics, Citing Late-Stage Pipeline Strength and Multi-Billion-Dollar Peak Sales Potential

Joseph Thome, an analyst from TD Cowen, has initiated a new Buy rating on Dyne Therapeutics (DYN). Joseph...

25d ago

DYN

Dyne Therapeutics Names Barry Greene Independent Board Director

Dyne Therapeutics ( ($DYN) ) has provided an update. On June 22, 2026, Dyne Therapeutics, Inc. appointed Barry...

29d ago

DYN

Dyne Therapeutics Expands Hercules Debt Facility for Flexibility

Dyne Therapeutics ( ($DYN) ) has provided an update. On June 16, 2026, Dyne Therapeutics entered into a...

1M ago

DYN

Dyne Therapeutics Expands Share Authorization After Stockholder Approvals

An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On June 5, 2026, Dyne Therapeutics, Inc....

1M ago

DYN

Acting FDA head vows to block political interference, Endpoint News says

Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas and senior staff....

2M ago

AZN

BMY

Analyst Reiterates Buy on Dyne Therapeutics, Maintains $44 Price Target on De-Risked Late-Stage Pipeline and Regulatory Momentum

LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Dyne Therapeutics today and set a price target...

2M ago

DYN

Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen

Dyne Therapeutics (DYN) announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE...

2M ago

DYN

Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy

Dyne Therapeutics ( ($DYN) ) just unveiled an update. On June 3, 2026, Dyne Therapeutics announced it has...

2M ago

DYN

FDA issues draft guidance to help accelerated cell, gene therapies for patients

The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene...

2M ago

AZN

BMY

Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline

Morgan Stanley analyst Michael Ulz has reiterated their bullish stance on DYN stock, giving a Buy rating today....

2M ago

DYN

DYN FAQ

What was Dyne Therapeutics, Inc.’s price range in the past 12 months?

Dyne Therapeutics, Inc. lowest stock price was $8.88 and its highest was $25.00 in the past 12 months.

What is Dyne Therapeutics, Inc.’s market cap?

Dyne Therapeutics, Inc.’s market cap is $3.92B.

When is Dyne Therapeutics, Inc.’s upcoming earnings report date?

Dyne Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.

How were Dyne Therapeutics, Inc.’s earnings last quarter?

Dyne Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.772 by $0.042.

Is Dyne Therapeutics, Inc. overvalued?

According to Wall Street analysts Dyne Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dyne Therapeutics, Inc. pay dividends?

Dyne Therapeutics, Inc. does not currently pay dividends.

What is Dyne Therapeutics, Inc.’s EPS estimate?

Dyne Therapeutics, Inc.’s EPS estimate is -0.75.

How many shares outstanding does Dyne Therapeutics, Inc. have?

Dyne Therapeutics, Inc. has 165,313,800 shares outstanding.

What happened to Dyne Therapeutics, Inc.’s price movement after its last earnings report?

Dyne Therapeutics, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.772. Following the earnings report the stock price went up 4.827%.

Which hedge fund is a major shareholder of Dyne Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DYN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dyne Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

49.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Dyne Therapeutics (DYN) Earnings & Revenues

Historic Earnings Reports

DYN Stock 12 Month Forecast

Average Price Target

$40.33

▲(97.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,23.96,26.13,28.299999999999997,30.47,32.64,34.81,36.98,39.15,41.32,43.489999999999995,45.66,47.83,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,23.216410256410256,24.642820512820514,26.06923076923077,27.495641025641028,28.922051282051285,30.34846153846154,31.774871794871796,33.20128205128205,34.627692307692314,36.054102564102564,37.48051282051282,38.90692307692308,{"y":40.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.79,21.96,22.13,22.3,22.47,22.64,22.81,22.98,23.15,23.32,23.49,23.66,23.83,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >